ECSP20078586A - Compuestos de azabencimidazol y productos farmacéuticos - Google Patents

Compuestos de azabencimidazol y productos farmacéuticos

Info

Publication number
ECSP20078586A
ECSP20078586A ECSENADI202078586A ECDI202078586A ECSP20078586A EC SP20078586 A ECSP20078586 A EC SP20078586A EC SENADI202078586 A ECSENADI202078586 A EC SENADI202078586A EC DI202078586 A ECDI202078586 A EC DI202078586A EC SP20078586 A ECSP20078586 A EC SP20078586A
Authority
EC
Ecuador
Prior art keywords
compounds
bladder
pharmaceutical products
pam
azabenzimidazole
Prior art date
Application number
ECSENADI202078586A
Other languages
English (en)
Inventor
Akiko FUJIBAYASHI
Kouya OIKAWA
Kazuhiko Wakita
Sho Hirai
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of ECSP20078586A publication Critical patent/ECSP20078586A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El propósito de la presente invención es proporcionar compuestos que tengan una acción M3 PAM. Ejemplos de la presente invención incluyen compuestos de azabencimidazol representados, por ejemplo, por la fórmula [I] y sus sales farmacológicamente aceptables. Estos compuestos tienen actividad M3 PAM. Además, debido a que estos compuestos tienen actividad M3 PAM, estos compuestos son útiles como agentes para la prevención o tratamiento de trastornos de micción y/o almacenamiento en vejiga hipoactiva, vejiga hipotónica, vejiga contráctil, subactividad del detrusor y vejiga neurogénica.
ECSENADI202078586A 2018-05-08 2020-12-07 Compuestos de azabencimidazol y productos farmacéuticos ECSP20078586A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018089867 2018-05-08

Publications (1)

Publication Number Publication Date
ECSP20078586A true ECSP20078586A (es) 2021-01-29

Family

ID=68467433

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202078586A ECSP20078586A (es) 2018-05-08 2020-12-07 Compuestos de azabencimidazol y productos farmacéuticos

Country Status (20)

Country Link
US (1) US20210371412A1 (es)
EP (1) EP3792260A4 (es)
JP (1) JP7235047B2 (es)
KR (1) KR20210006437A (es)
CN (1) CN112368282B (es)
AU (1) AU2019265134B2 (es)
BR (1) BR112020022662A2 (es)
CA (1) CA3099655A1 (es)
CL (1) CL2020002868A1 (es)
CO (1) CO2020013848A2 (es)
EC (1) ECSP20078586A (es)
IL (1) IL278517B1 (es)
MA (1) MA52587A (es)
MX (1) MX2020011855A (es)
PE (1) PE20211384A1 (es)
PH (1) PH12020551873A1 (es)
SG (1) SG11202011003TA (es)
TW (1) TW202016108A (es)
UA (1) UA126774C2 (es)
WO (1) WO2019216294A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3161582A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
CN114901283A (zh) * 2019-11-13 2022-08-12 日本新药株式会社 功能性消化道障碍和口腔干燥症的治疗剂和预防剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
BRPI0906556A2 (pt) * 2008-01-24 2015-07-07 Ucb Pharma Sa Composto, e, composição farmacêutica
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規２環性複素環化合物からなる医薬
CA2821819A1 (en) * 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds

Also Published As

Publication number Publication date
AU2019265134B2 (en) 2024-02-29
EP3792260A4 (en) 2022-02-09
PH12020551873A1 (en) 2021-05-31
JP7235047B2 (ja) 2023-03-08
AU2019265134A1 (en) 2020-12-17
SG11202011003TA (en) 2020-12-30
TW202016108A (zh) 2020-05-01
KR20210006437A (ko) 2021-01-18
CO2020013848A2 (es) 2021-01-29
MA52587A (fr) 2021-03-17
WO2019216294A1 (ja) 2019-11-14
EP3792260A1 (en) 2021-03-17
UA126774C2 (uk) 2023-02-01
IL278517A (en) 2020-12-31
US20210371412A1 (en) 2021-12-02
CA3099655A1 (en) 2019-11-14
BR112020022662A2 (pt) 2021-02-09
JPWO2019216294A1 (ja) 2021-05-13
MX2020011855A (es) 2021-01-20
PE20211384A1 (es) 2021-07-27
CN112368282A (zh) 2021-02-12
CL2020002868A1 (es) 2021-04-16
IL278517B1 (en) 2024-05-01
CN112368282B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2017011038A2 (es) Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca”
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
CO2017002292A2 (es) Compuestos y composiciones como inhibidores de quinasa raf
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
DOP2016000291A (es) Composiciones y métodos para modular la expresión del factor b del complemento
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
ECSP20078586A (es) Compuestos de azabencimidazol y productos farmacéuticos
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
AR092247A1 (es) INHIBIDORES DE LA b-SECRETASA
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo